CVM - CEL-SCI spikes as U.K. picks cancer drug Multikine for review
2023-12-04 12:24:52 ET
More on Cel-Sci
- CEL-SCI climbs after ESMO data for lead asset Multikine
- Seeking Alpha’s Quant Rating on Cel-Sci
- Historical earnings data for Cel-Sci
- Financial information for Cel-Sci
For further details see:
CEL-SCI spikes as U.K. picks cancer drug, Multikine for review